{
    "doi": "https://doi.org/10.1182/blood.V126.23.4210.4210",
    "article_title": "Prevalence of Oligoclonal Bands in Multiple Myeloma Patients Who Achieved Better Results Than Very Good Partial Response after Treatment with Standard or High Doses Chemotherapy-Final Analysis ",
    "article_date": "December 3, 2015",
    "session_type": "651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster III",
    "abstract_text": "Introduction - Oligoclonal bands (OB) are monoclonal proteins distinct from those originally identified in the multiple myeloma (MM) diagnosis. Some authors consider that appearance of these bands confers a better prognosis and may be linked to immune reconstitution. There is no data of the exact prevalence of OB emergence in patients with very good partial response (VGPR) or better after different treatment schedules. Objectives - To determine the prevalence of OB in MM patients treated with or without high-dose chemotherapy that obtained at least VGPR and its prognostic value. Methods- This is a retrospective and prospective cohort study. Data were collected from records of patients that achieved at least VGPR to identify the OB emergence. Subsequently, new sample collections from the positive patients were made in order to monitor the progress and duration of the maintenance of these bands. Results- Median follow-up was 42m and 101 patients were included. Median age was 58y (29-87) and 55% were male. IgG was the most frequent component (60%). Durie-Salmon IIIA/B was identified in 92% of the population; ISS was 33% in stage I, 30% in stage II, and 31% in stage III. The prevalence of OB identified by SPE and IF was 50.5% (51 cases), with a higher prevalence in those who underwent transplantation and those who achieved complete response (p=0.00139 and p=0.0368, respectively). Progression free survival (PFS) was longer in the OB group (45.4m x 34.7m p = 0.0075). Conclusion - The OB prevalence in this population was 50.5% and oligoclonality resulted in a longer PFS. Figure 1. View large Download slide Figure 1. View large Download slide  Close modal Disclosures No relevant conflicts of interest to declare.",
    "topics": [
        "aftercare",
        "chemotherapy regimen",
        "multiple myeloma",
        "oligoclonal bands",
        "partial response",
        "complete remission",
        "follow-up",
        "immunoglobulin g",
        "monoclonal immunoglobulin",
        "protein electrophoresis, serum"
    ],
    "author_names": [
        "Luiza soares Vieira, MD",
        "Edvan de queiroz Crusoe, MD MsC",
        "Manuella de S. Sampaio Almeida, MD PhD",
        "Lais Sousa, MD",
        "ana Lucia Perez, MD",
        "Priscilla Cury, MD",
        "Marina Rossato, MD",
        "Fabiana Higashi, MD",
        "ana Luiza Dias, MD",
        "anna Carolina Castro, MD",
        "Carlos Chiattone, MD PhD",
        "Vania T M Hungria, MDPhD"
    ],
    "author_dict_list": [
        {
            "author_name": "Luiza soares Vieira, MD",
            "author_affiliations": [
                "Disciplina de Hematologia e Oncologia da Faculdade de Ci\u00eancias M\u00e9dicas da Santa Casa de S\u00e3o Paulo, sao paulo, Brazil "
            ],
            "author_rank": 1,
            "first_author": 1,
            "last_author": 0
        },
        {
            "author_name": "Edvan de queiroz Crusoe, MD MsC",
            "author_affiliations": [
                "Disciplina de Hematologia e Oncologia da Faculdade de Ci\u00eancias M\u00e9dicas da Santa Casa de S\u00e3o Paulo, sao paulo, Brazil ",
                "Hospital Universit\u00e1rio Professor Edgar Santos- Universidade Federal da Bahia-HUPES-UFBA, salvador, Brazil "
            ],
            "author_rank": 2,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Manuella de S. Sampaio Almeida, MD PhD",
            "author_affiliations": [
                "Disciplina de Hematologia e Oncologia da Faculdade de Ci\u00eancias M\u00e9dicas da Santa Casa de S\u00e3o Paulo, sao paulo, Brazil "
            ],
            "author_rank": 3,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Lais Sousa, MD",
            "author_affiliations": [
                "Federal University of Bahia, Salvador, Brazil "
            ],
            "author_rank": 4,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "ana Lucia Perez, MD",
            "author_affiliations": [
                "Disciplina de Hematologia e Oncologia da Faculdade de Ci\u00eancias M\u00e9dicas da Santa Casa de S\u00e3o Paulo, sao paulo, Brazil "
            ],
            "author_rank": 5,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Priscilla Cury, MD",
            "author_affiliations": [
                "Disciplina de Hematologia e Oncologia da Faculdade de Ci\u00eancias M\u00e9dicas da Santa Casa de S\u00e3o Paulo, Sao Paulo, Brazil "
            ],
            "author_rank": 6,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Marina Rossato, MD",
            "author_affiliations": [
                "Disciplina de Hematologia e Oncologia da Faculdade de Ci\u00eancias M\u00e9dicas da Santa Casa de S\u00e3o Paulo, sao paulo, Brazil "
            ],
            "author_rank": 7,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Fabiana Higashi, MD",
            "author_affiliations": [
                "Disciplina de Hematologia e Oncologia da Faculdade de Ci\u00eancias M\u00e9dicas da Santa Casa de S\u00e3o Paulo, SAO PAULO, Brazil "
            ],
            "author_rank": 8,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "ana Luiza Dias, MD",
            "author_affiliations": [
                "Disciplina de Hematologia e Oncologia da Faculdade de Ci\u00eancias M\u00e9dicas da Santa Casa de S\u00e3o Paulo, sao paulo, Brazil "
            ],
            "author_rank": 9,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "anna Carolina Castro, MD",
            "author_affiliations": [
                "Disciplina de Hematologia e Oncologia da Faculdade de Ci\u00eancias M\u00e9dicas da Santa Casa de S\u00e3o Paulo, sao paulo, Brazil "
            ],
            "author_rank": 10,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Carlos Chiattone, MD PhD",
            "author_affiliations": [
                "Disciplina de Hematologia e Hemoterapia, Faculdade de Ci\u00eancias M\u00e9dicas da Santa Casa de S\u00e3o Paulo, S\u00e3o Paulo, Brazil "
            ],
            "author_rank": 11,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Vania T M Hungria, MDPhD",
            "author_affiliations": [
                "Disciplina de Hematologia e Oncologia da Faculdade de Ci\u00eancias M\u00e9dicas da Santa Casa de Miseric\u00f3rdia S\u00e3o Paulo, Sao Paulo, Brazil"
            ],
            "author_rank": 12,
            "first_author": 0,
            "last_author": 1
        }
    ],
    "datetime_abstract_obtained": "2022-06-04T09:28:50",
    "is_scraped": "1"
}